Introduction: Orlistat, the first of a new class of drugs for the treatment of obesity, was launched in the UK in December 1998. The prescribing information recommends that treatment with orlistat should be discontinued after 12 weeks if the patient has not achieved a specified loss of weight. Objective: To monitor the safety of orlistat prescribed in the primary care setting in England using prescription-event monitoring (PEM). Methods: A postmarketing surveillance study using the observational cohort technique of PEM. Patients were identified from dispensed prescriptions issued by primary care physicians for orlistat between December 1998 and November 1999. The outcome data were event reports obtained by sending questionnaires (green forms) to the prescribing doctor at least 6 months after the first prescription for an individual patient. Incidence densities, expressed as number of first reports of an event/1000 patient-months of exposure, were calculated. Significant differences between incidence densities (IDs) for events reported in the 1st month (ID 1 ) and months 2 and 3 (ID 2-3 ) of exposure were regarded as potential signals. Reasons for stopping orlistat were analysed. Follow-up information was requested for selected events and used to assess the causal association with orlistat. Results: Green forms containing clinically useful information on 16 021 patients (median age 45 years (interquartile range 35-54); 80.1% females) were received. The events reported most frequently during the 1st month of treatment were 'not effective' (639; 4.0% of cohort), diarrhoea (371; 2.3%) and weight loss (230; 1.4%). Twelve clinical adverse events were identified for which ID 1 was significantly greater than ID 2-3 . These included non-specific events (e.g. intolerance, malaise/ lassitude, unspecified side effects), weight loss and vaginitis/vulvitis. The remaining events were gastrointestinal in nature and included diarrhoea, pain abdomen, flatulence, nausea/vomiting, rectal discharge, faecal incontinence and 'gastrointestinal unspecified' events. A similar pattern of predominately gastrointestinal events was seen for reasons for stopping and suspected adverse drug reactions. Review of selected events for causality revealed 45 events which were assessed as possibly or probably related to orlistat. Conclusions: This study shows that orlistat is fairly well tolerated. The safety profile of orlistat was similar to the prescribing information and experience reported in the literature.
Introduction
In December 1998, orlistat, the first of a new class of drugs for the treatment of obesity, was launched in the UK. Orlistat is a chemically synthesised derivative of lipostatin, an inhibitor of gastric and pancreatic lipases, which inhibits the cleavage of triglycerides and prevents absorption of up to 30% of ingested fat. 1 This fat is excreted in the faeces leading to weight loss. Orlistat is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) X30 kg/m 2 , or overweight patients (BMI X28 kg/m 2 ) with associated risk factors. [2] [3] [4] The prescribing information recommends that treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of their body weight as measured at the start of drug therapy. 4 Published studies have shown that treatment with orlistat improves many outcome measures such as decrease in cholesterol and LDL cholesterol levels, lowering of both systolic and diastolic blood pressure and finally improvement in glycaemic control and reductions in cardiovascular risk factors in patients with Type 2 diabetes. 5, 6 Postmarketing surveillance is essential because the safety database on newly licensed drugs is limited by both the number and characteristics of the patients involved in prelaunch clinical studies. 7 The Drug Safety Research Unit (DSRU) provides a postmarketing drug surveillance scheme, which monitors the safety of newly marketed drugs during their immediate postmarketing period in England, using the observational cohort technique of prescription-event monitoring (PEM). 7 This paper reports the results of a PEM study undertaken to monitor the safety of orlistat as used by primary care physicians (GPs) in England.
Materials and methods
Prescription-event monitoring is an observational cohort study; the methodology is described in detail elsewhere. 7 Patients were identified by means of dispensed primary care National Health Service (NHS) prescription data for orlistat supplied in confidence by the Prescription Pricing Authority (PPA) in England between December 1998 and November 1999. A simple questionnaire (green form) was sent to the prescribing GP at least 6 months after the DSRU was notified by the PPA of the date of the first dispensed prescription for an individual patient. The green form requested information on age, indication, dose, effectiveness, duration of treatment (start and stop dates), reasons for stopping if applicable and any significant events (on or off drug) after orlistat was prescribed, including events suspected to be an adverse drug reaction (ADR). The term, 'event' is defined as including any new diagnosis, any reason for referral to a consultant or admission to hospital, any unexpected deterioration (or improvement) in a concurrent illness, any suspected drug reaction, any alteration of clinical importance in laboratory values or any other complaint of sufficient importance to enter in the patient's notes. Events were coded using the DSRU event dictionary, a hierarchical dictionary, with verbatim terms used by the GPs grouped under 'lower level' and 'higher level' terms within a system organ class (SOC). Those questionnaires returned with no information (clinical or other) provided were classified as 'void' and excluded from the study cohort and subsequent analysis, as there was no means of determining whether forms not completed indicated no reported events.
Each green form returned was reviewed by a DSRU research fellow and the circumstances of each event assessed. Any events of clinical interest based on information available on the safety profile of orlistat at the time the study was undertaken or considered medically important were followed up by sending additional questionnaires to the prescribing GP. In addition, pregnancies were followed-up. Further information was also sought on cases where the patient had died but the cause of death was not reported. If no reply to the follow-up questionnaire was received, one reminder was sent 8 weeks after the initial questionnaire was sent. Individual case reports were assessed for causality by a clinical research fellow according to DSRU procedure using six criteria (temporality, pharmacological plausibility, clinical and pathological characteristics of the event, exclusion of other possible causes, the effects of dechallenge and rechallenge) and four categories (probable, possible, unlikely or not assessable). These criteria are generally similar to those included in the WHO definitions. 8 
Statistical analysis
Incidence densities (IDs) were calculated for all reported events during treatment within specified time periods and expressed as the number of first reports of an event per 1000 patient-months of exposure. IDs for events occurring in the 1st month of treatment (ID 1 ), during months 2-3 of treatment (ID 2-3 ) and for events occurring during the overall treatment period (ID A ) were calculated. Patient-months of exposure were based on those patients for whom either the date of stopping the drug was known or who continued to take the drug until the end of the study period. The difference between ID 1 and ID 2-3 and the 99% confidence intervals for this difference were calculated. A significant positive difference between ID 1 and ID [2] [3] showed that the rate of events during month 1 was significantly greater than during months 2-3 thus indicating that the event may have been associated with starting orlistat. The time periods were chosen in view of the recommendation in the prescribing information for orlistat to be discontinued after 12 weeks of treatment if the patient had not achieved a specified loss in weight. 4 
Power
The ability to detect an event is dependent on the expected incidence of the event in those exposed to the drug, the background rate in those not exposed to the drug, and the total number of patients. A cohort of at least 10 000 patients was desirable for this study. This number would allow 95% certainty that events not observed in the cohort occurred less frequently than one in 3333 cases. 9 A cohort of 10 000 should allow for the detection of at least three cases of an event with 85% power, if the event occurs at a rate of at least one in 2000 patients (assuming the background rate is zero). 10 If the background rate of an event was one in 1000, a cohort of 10 000 patients would enable detection of an event occurring at a rate of one in 500, with 80% power. 11 It is noted that the background rate for a diversity of events is often unknown. 
Results

Cohort size
Green forms were sent for 35 304 patients who commenced treatment with orlistat between December 1998 and November 1999; 17 689 (50.1%) were returned and clinically useful information was provided on 16 021 green forms (45.4%). The most frequent reasons for excluding green forms from the analysis were that the patient was no longer registered with the GP, the form was returned blank or the GP had no record of the patient taking the drug. Therefore, the total number of patients included in the cohort for analysis was 16 021.
Patient demographics
Overall, the median age was 45 years (interquartile range (IQR) 35-54); age was not recorded for 3604 patients (22.5%). The age distribution is given in Figure 1 . 12 831 (80.1%) patients were females who were younger (median 44 years IQR 34-53) than male patients (median 49 years IQR 39-56). The sex was not recorded for 83 (0.5%) of the patients. The cohort included 70 patients aged 17 years or below (0.4% of cohort); only one patient was below 12 years of age. The prescribing information for orlistat provides dosing guidelines for adults and states that orlistat is not intended to be used in children. 4 Indication, dose and effectiveness The major specified primary indication was the licensed indication obesity (10 819; 67.5%). 4 The indication was not specified for 32.1% (5143) of patients. Of the 11 883 patients for whom information on dose was given, 9143 (76.9%) were started at the recommended 360 mg/day dose. 4 2695 patients (22.7%) were started on a dose below 360 mg/day and 45 (0.4%) patients were started on a dose of more than 360 mg/ day. For 26 of the 11 883 patients, the dose given on the green form was not a multiple of the available tablet size and the most likely explanation is that the GP made an error in entering the data on the green form. The median duration of treatment was 150 days (IQR: 62-268 days).
Suspected adverse drug reactions
Three hundred and sixty eight events in 315 (2.0% of cohort) patients were recorded on the green form as ADRs. The most frequently reported ADRs were 'unspecified side effects', where the GP had not specified the nature of the adverse event, and gastrointestinal events (Table 1 ). There were five reports of suspected drug interactions. In two cases, involving metformin and terbinafine, respectively, no events were specified. In the remaining three cases, rectal bleeding was reported with methotrexate, diarrhoea with fluoxetine and recurrent contraceptive failure with an unspecified contraceptive.
Reasons for stopping
In view of the recommendation in the prescribing information to discontinue treatment with orlistat after 12 weeks if the patient has not achieved a specified loss in weight, reasons for stopping within 3 months of starting treatment and for the entire study period are presented. 4854 patients stopped orlistat during the first 3 months of treatment (30.3% of cohort); reasons for stopping were specified for 3299 patients (20.6%). The most frequently reported reasons were 'not effective' in 1695 patients (10.6% Gastrointestinal events for which there is currently no specific lower level term in the DSRU dictionary.
Safety profile of orlistat NV Acharya et al of cohort), diarrhoea (332; 2.1%) and 'patient request' (308; 1.9%). Over the entire treatment period, 11 049 patients (68.9% of cohort) stopped treatment with orlistat; reasons for stopping were specified for 8093 patients (50.5%). The most common reasons for stopping were 'not effective' in 4313 patients (26.9% of cohort), condition improved (698; 4.3%) and patient request (676; 4.2%). Gastrointestinal event(s) were given as a reason for stopping in 893 patients (5.6% of cohort) over the entire study period. Table 2 shows the adverse events most frequently given as reasons for stopping during the two time periods. The clinical events include those associated with the indication (weight gain), gastrointestinal events, non-specific events (intolerance; malaise/lassitude, unspecified side effects), headache and pregnancy.
Statistical analysis of events
The events reported most frequently during the 1st month of treatment were 'not effective' (639; 4.0% of cohort), diarrhoea (371; 2.3%) and weight loss (230; 1.4%) ( Table 3) . The clinical adverse events for which ID 1 ÀID 2-3 was significantly greater than 0 at the P ¼ 0.01 level were: diarrhea, weight loss, pain abdomen, intolerance, flatulence, nausea/vomiting, rectal discharge (see Table 3 ), faecal incontinence (not shown), unspecified side effects (not shown), malaise/lassitude (not shown), 'gastrointestinal unspecified' (not shown) and vaginitis/vulvitis (not shown). Nausea/vomiting and vaginitis/vulvitis were not listed in the summary of product characteristics (SPC) at the time of marketing. There were 54 cases of vaginitis/vulvitis during treatment with orlistat. Follow-up was not requested for these cases. The information on vaginitis/vulvitis provided below is based on green forms. Unlike follow-up questionnaires, data on medical history and concurrent medications is not routinely collected on green forms. Age was not known for 11 of the 54 cases. The median age of patients was 37 years (range 25-74). There were four cases with a possible hormonal cause. In four cases, urinary symptoms were reported, including one case where a urinary tract infection No. of patients who stopped treatment within 3 months of starting orlistat and for whom the reason(s) for stopping treatment was given. b No. of patients who stopped treatment at any time during the study and for whom the reason(s) for stopping was given. Safety profile of orlistat NV Acharya et al was also described (use of an antibiotic was not referred to on the green form for this case). In a further case, a possible hormonal cause and urinary symptoms were described. There were 10 cases where an infection, not involving the urinary tract, was reported during the 4-week period preceding the reporting of vaginitis or vulvitis; use of an antibiotic was described in three cases. Table 4 presents 45 events which were assessed as possibly or probably related to treatment with orlistat based primarily on follow-up information received from the prescribing GP. The highest proportion of these events fell under the skin SOC (11; 24.4%) and the cardiovascular SOC (10; 22.2%). Under the skin SOC, cases of erythema, pruritus, rash and urticaria were indicative of an allergic or hypersensitivity reaction. In all but two of these cases the events occurred within 1 month of starting orlistat. The events were assessed as possibly or probably related to orlistat predominately on the basis of temporality and/or positive dechallenge. Under the cardiovascular SOC, the three reports of hypertension involved patients aged 42-52 years of age. Two patients were not known to be hypertensive before starting orlistat and one had a history of hypertension but screening tests on starting orlistat were reported to be normal. The case of oedema involved a 52-year-old female with no apparent risk factors. She developed mild pedal oedema, however, oedema was also reported after orlistat was stopped and treatment with diuretics was required. The three reports of swelling of the ankles concerned patients aged 48-60 years. No alternative explanation was available for one case. The remaining two cases concerned one patient with a history of swelling of the ankles and one patient with ischaemic heart disease. For the cases of a cardiovascular event described above, causality was predominately based on temporality and/or lack of alternative explanation or persistence of event during treatment. Orlistat was not known to have been discontinued in any case.
Selected events
Under the eye SOC, causality for the case of hemianopia, which was associated with headache, and that of vitreous haemorrhage was based on temporality (time to onset 4 and 8 weeks, respectively) and lack of alternative explanation. Causality was based on temporality (time to onset 7 days) for the case of retinal vein thrombosis involving a 72-year-old female, with a history of borderline hypertension.
Of the two reports of abnormal liver function tests, the first case was assessed as possibly related on the basis of temporality. Abnormal alanine aminotransferase and gamma glutamyl transferase (GGT) readings were detected during routine investigations 1 month after the patient started treatment, however, the event did not resolve on stopping orlistat. In the second case assessed as probably related to orlistat, there was a positive rechallenge. Reports with evidence to suggest that event is not drug related were not followed up. b The difference in numbers between events followed up and those assessed as possibly or probably related to orlistat is accounted for by events assessed as unlikely to be related and events which were not assessable as a result of nonresponse or incomplete follow-up.
c Assessed on basis of information on green form. GP reported that a 38-year-old female had a single episode of demyelination 122 days after starting orlistat. Treatment was discontinued as a result of this event. GP considered event was a suspected ADR and had reported it to UK spontaneous reporting scheme, hence assessed as possible adverse drug reaction. 
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No cases of hepatitis or jaundice were considered for followup based on the information provided on the green form by the GP.
The two reports of hypothyroidism were assessed as possibly related on the basis of temporality; abnormal readings were detected 3-4 months after starting orlistat. The first patient was reported to have no risk factors. The second patient was taking multiple concurrent medications. Both patients continued treatment with orlistat.
Pregnancies
The outcomes of 109 pregnancies are presented in (Table 5) . Sixty seven pregnancies were initially exposed to orlistat during the first trimester and two during the second trimester. Of the rest, orlistat had been stopped before the last menstrual period (LMP) in 35 pregnancies and the exposure was uncertain in the five remaining pregnancies.
Three babies were born with congenital anomalies; one with congenital dislocation of the hips, the mother stopped taking orlistat 8 weeks after the LMP; one with translocation of the great vessels; the mother stopped taking orlistat approximately 8 weeks after the LMP; she also had diabetes and changed from metformin and acarbose to insulin approximately 3 months after the LMP; one baby who subsequently developed 'colic' was found to have 'malrotation' which needed surgery; the mother had taken orlistat for approximately 10 days during the 4th-6th weeks of her pregnancy. One other baby had shoulder dystocia at birth which resulted in a fractured clavicle and also neonatal jaundice requiring phototherapy. The mother stopped taking orlistat approximately 1 month after the LMP.
Deaths
Thirty three deaths were reported during the total period of observation, irrespective of whether the patient died while taking orlistat or after stopping treatment. The causes of death were ascertained for 28 of the patients. Cardiovascular events led to 15 deaths, while respiratory (pulmonary) events accounted for three deaths. Three deaths were due to cerebrovascular events, three due to cancer and four due to other causes. None of the deaths were reported to be due to orlistat.
Discussion
This PEM study describes a population prescribed orlistat under primary care conditions in England, a summary of the events reported during use and possible signals of interest. Clinical information on 16 021 patients was gathered. The patients were predominately female (80.1%); the median age was 44 years for females and 49 years for males.
Prescription-event monitoring does not interfere in the prescribing decisions of the GPs, or specify strict inclusion criteria that occur for controlled clinical trials. Thus, a strength of this study is that it provides information on the general practice use of orlistat regardless of the patient's age, past medical history or concomitant medication. Furthermore, by asking GPs to supply 'event' data without causality assessments, the study design was capable of identifying signals which none of the participating GPs suspected to have been due to an ADR.
The response rate for all green forms returned for this study was 50.1% which is lower than the average response rate for PEM studies (57.4%). While the response rate for green forms containing clinically useful information was 45.4%. This response rate is still substantial compared with the proportion of suspected ADRs which are reported in spontaneous ADR reporting schemes. 16, 17 For data collection systems that are dependent on a third party, such as PEM, response bias is likely. 7 Under-reporting, including of serious or fatal events is possible in PEM. This study identified 12 adverse events which occurred significantly more often during the 1st month of treatment compared to months 2-3 and therefore may have been associated with starting orlistat. These events included gastrointestinal events, non-specific events (e.g. intolerance, malaise/lassitude), weight loss and vaginitis/vulvitis. Weight loss is associated with the indication. With the exception of nausea/vomiting, vaginitis/vulvitis and the two non-specific events listed above, the remaining events were listed under undesirable effects in the SPC for orlistat current at the time of marketing. 4 Neither nausea/vomiting, or vaginitis/vulvitis have been added to the SPC since marketing. 18 The rates of gastrointestinal events occurring during the treatment period were lower than those observed in clinical trials. 19, 20 In clinical trials orlistat treatment was associated with gastrointestinal adverse events including oily spotting from the rectum (27%), flatus with discharge (24%), faecal Safety profile of orlistat NV Acharya et al urgency (22%) and faecal incontinence (8%). 5, 6 In this study, diarrhoea was the most frequently reported gastrointestinal event with 4.9% (789) of patients reported to have experienced this event during treatment. The other gastrointestinal events described above were each reported in o1% of patients in this study: flatulence (122; 0.8%); faecal incontinence (86; 0.5%) rectal discharge (77; 0.5%). In this study, reports of these events might be underestimated due to lack of proactive contact with the patient to elicit these events and the possibility of under-reporting by GPs. In clinical trials, most subjects experienced only one or two episodes and most gastrointestinal events were mild to moderate in intensity, occurred early during treatment, and resolved spontaneously. In this study, gastrointestinal events were given as a reason for stopping treatment in 893 patients (5.6% of cohort) which is comparable to the risks observed in clinical trials (5.4-11.7%). The gastrointestinal events most frequently given as reasons for stopping over the entire PEM study were: diarrhoea (3.3% of cohort), abdominal pain (0.6%) and flatulence (0.5%).
Through follow-up of selected events, 45 were assessed as possibly or probably related to treatment with orlistat. One of the events, abdominal pain, was listed in the SPC for orlistat at the time of marketing. 4 Hypersensitivity reactions, which in this study were identified as a signal through the review of follow-up information, have been added to the SPC since marketing as rare undesirable effects based on postmarketing spontaneous reports. 18 The spectrum of hypersensitivity reactions given in the SPC ranges from pruritus, rash, urticaria and angioedema to bronchospasm and anaphylaxis. In this study, events such as rash, pruritus and urticaria were assessed as possibly or probably related to use of orlistat. However, no reports of more severe hypersensitivity reactions, such as anaphylaxis or angioedema were assessed as causally related to orlistat. No cases of StevensJohnson syndrome or toxic epidermal necrolysis were received in this study. Hepatobiliary disorders, including hepatitis and an increase in liver transaminases and in alkaline phosphatase, have been added to the SPC as very rare undesirable effects on the basis of postmarketing spontaneous reports. 18 Two cases of abnormal liver function tests were assessed as possibly or probably related to orlistat in this study. The possible confounding effect associated with obesity makes it difficult to assess the impact of the few reports of hypertension which could possibly have associations with orlistat. In this study, the majority of the cases of hypertension assessed for causality had a history of hypertension. Hypertension is the most common obesity-related disease. 21 A case report of new-onset hypertension and peripheral oedema during treatment with orlistat has been published, however, there is disagreement over the cause of further episodes of oedema in this patient after treatment with orlistat was stopped. [22] [23] [24] One report of oedema and three reports of swelling of the ankles were assessed as causally related to orlistat in our study. The two reports of hypothyroidism are difficult to evaluate as there was no diagnostic laboratory data available before orlistat was started. These reports were assessed as possibly related to orlistat on the basis of temporality, however, the patients may have been borderline hypothyroid before treatment as exhibited by their obesity. The significance of single cases of events assessed as possibly or probably related to orlistat in our study is difficult to evaluate. The association between obesity and recognized co-morbid conditions needs to be considered in addition to the background risk of events in the general population. The findings from this study must be placed in context with those of other studies.
Long-term studies have demonstrated a favourable safety profile of orlistat, except for gastrointestinal adverse events, which is consistent with our findings. [25] [26] [27] In conclusion, this postmarketing surveillance study shows that orlistat is fairly well tolerated when used in general practice in England. A number of signals were identified, some of these events have been added to the SPC since marketing. The safety profile of orlistat was similar to the prescribing information and experience reported in the literature.
